PrEP

A new study conducted by CDC investigators found that commercially insured patients persisted on PrEP for median time of 13.7 months, compared to 6.8 months among Medicaid patients.

A new commentary argues that given the strong safety and efficacy profile of TDF/FTC, there is not sufficient benefit to warrant changing clinician emphasis to TAF/FTC.

New legislation, cost assistance program will likely reduce transmission.

Viral suppression at 2 years nearly doubled for people with HIV in a medical care coordination program implemented by the Los Angeles County Division of HIV and STD Programs, a new study found.

Contagion® counts down the top HIV news stories of 2019, including FDA approvals, breakthrough discoveries, recommendations from the frontlines, and a big-picture look at just how close we are to ending the epidemic.

A new study out of Africa demonstrates that maternal-child clinics may act as a one-stop shop for both pregnancy and postpartum concerns and HIV protection.

The FDA has issused a complete response letter to ViiV Healthcare for cabotegravir/rilpivirine.

An analysis shows that during 2016-17, 14% of people living with HIV have used a drug-cost saving strategy and 7% have had cost saving-related nonadherence.

Results suggest that PrEP provision is concentrated among those at high risk for HIV and STIs, but that more must be done to prevent STIs among those who persistently use PrEP.

Recommendations to offer antiretroviral therapy on the same day as home-based HIV testing were reinforced by a 2-year follow-up study that examined involvement in care and viral suppression.

Jason Tokumoto, MD, discusses recent developments in HIV treatment and prevention, focusing on the impact of “U=U.”

Jason Schafer, PharmD, MPH, BCPS AQ-ID, discusses upcoming long-acting therapies for HIV.

Something novel in infectious diseases practice has occurred and, like many big changes, it is not without controversy.

An analysis of participants in a trial measuring the efficacy of PrEP found that sex-driven dose timing—as opposed to daily dosing—was effective in preventing HIV, even in men who had sex less often.

Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, previews his editor-in-chief letter for the December issue.

In April, the US Food and Drug Administration (FDA) approved dolutegravir plus lamivudine as a complete 2-drug regimen for treatment naïve adults with HIV-1.

Gregory Felzien, MD, AAHIVS, highlights “clinic champions” who help move patient care forward while facing external constraints.

Investigators have documented growing acceptability among sexual minority men that U=U, but with widespread overestimation of transmission risk.

Carlos del Rio, MD, discusses advances in long-acting antiretrovirals and the costs associated with HIV therapies.

Fifteen years after the launch of a program to help bring HIV treatment to low-income countries, an FDA analysis shows the program is working, but there is room for improvement.

Novel modes of delivery are imperative to improve HIV suppression and prevent transmission.

CDC investigators used HIV surveillance and pharmacy data to examine the status of HIV treatment and prevention in the United States.

On December 3, 2019, the US Department of Health and Human Services announced the launch of program which will provide PrEP to people without prescription drug insurance coverage.

Authors of a new report published by CDC detail barriers to case-based surveillance in policy and technical infrastructure which need to be addressed in order to enhance national efforts surrounding the HIV epidemic.

Treatment-naive patients who are prescribed INSTI-based ART experienced weight gain and systolic blood pressure increases higher than peers on other forms of ART.

Results from a new study indicate that early antiretroviral therapy treatment provides measurable benefits in infants who acquired HIV via vertical transmission.

On December 1, 2019, international health organizations reflect on the advancements of the HIV/AIDS research field and acknowledge the challenges that still remain.

The survey was designed to provide more information on beliefs and perceptions toward HIV among Generation Z and millennials in the United States.

Distributing free HIV self-tests to men who have sex with men resulted in a sharp increase in the number of infections identified, a new study by the CDC.

A new study has discovered that PrEP use is associated with lower levels of HIV anxiety in men, a benefit which could be incorporated into initiatives to increase PrEP uptake.